A predictive ligand-based Bayesian model for human drug-induced liver injury

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2302-2308

  Ekins, Sean ^a,b,c   Williams, Antony J ^d   Xu, Jinghai J ^e  

^a Collaborations in Chemistry ^*  (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d ROYAL SOCIETY OF CHEMISTRY   (United Kingdom)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIOLEOYLPHOSPHATIDIC ACID; KETONE; LIGAND; STYRENE;

ARTICLE; BAYES THEOREM; COMPUTATIONAL FLUID DYNAMICS; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRAINING; VALIDATION STUDY;

BAYES THEOREM; DRUG-INDUCED LIVER INJURY; HUMANS; LIGANDS;

EID: 78649621062     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035113     Document Type: Article

References (47)

1. Baell JB and Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719-2740.
2. Bender A (2005) Studies on Molecular Similarity, University of Cambridge, Cambridge. UK.
3. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, and Jenkins JL (2007) Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Chem Med Chem 2:861-873.
4. Blake JF (2005) Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. Med Chem 1:649-655.
5. Boelsterli UA (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192:307-322.
6. Boelsterli UA, Ho HK, Zhou S, and Leow KY (2006) Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 7:715-727.
7. Cheng A and Dixon SL (2003) In silico models for the prediction of dose-dependent human hepatotoxicity. J Comput Aided Mol Des 17:811-823.
8. Clark RD, Wolohan PR, Hodgkin EE, Kelly JH, and Sussman NL (2004) Modelling in vitro hepatotoxicity using molecular interaction fields and SIMCA. J Mol Graph Model 22:487-497.
9. Cruz-Monteagudo M, Cordeiro MN, and Borges F (2008) Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity. J Comput Chem 29:533-549.
10. Durham JA, Gandolfi AJ, and Bentley JB (1984) Hepatotoxicological evaluation of dantrolene sodium. Drug Chem Toxicol 7:23-40.
11. Ekins S, Andreyev S, Ryabov A, Kirillov E, Rakhmatulin EA, Sorokina S, Bugrim A, and Nikolskaya T (2006) A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos 34:495-503.
12. Ekins S, Berbaum J, and Harrison RK (2003) Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab Dispos 31:1077-1080.
13. Ekins S, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Hohman M, and Bunin BA (2010) A collaborative database and computational models for tuberculosis drug discovery. Mol Biosyst 6:840-851.
14. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, and Wikel JH (2000) Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44:251-272.
15. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, and Tropsha A (2010a) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol 23:171-183.
16. Fourches D, Muratov E, and Tropsha A (2010b) Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model 50:1189-1204.
17. Greene N, Fisk L, Naven RT, Note RR, Patel ML, and Pelletier DJ (2010) Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 23:1215-1222.
18. Hann M, Hudson B, Lewell X, Lifely R, Miller L, and Ramsden N (1999) Strategic pooling of compounds for high-throughput screening. J Chem Inf Comput Sci 39:897-902.
19. Hassan M, Brown RD, Varma-O'brien S, and Rogers D (2006) Cheminformatics analysis and learning in a data pipelining environment. Mol Divers 10:283-299.
20. Huth JR, Mendoza R, Olejniczak ET, Johnson RW, Cothron DA, Liu Y, Lerner CG, Chen J, and Hajduk PJ (2005) ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J Am Chem Soc 127:217-224.
21. Huth JR, Song D, Mendoza RR, Black-Schaefer CL, Mack JC, Dorwin SA, Ladror US, Severin JM, Walter KA, Bartley DM, et al. (2007) Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance. Chem Res Toxicol 20:1752-1759.
22. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, et al. (2002) Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4:E25.
23. 5). Drug Metab Dispos 35:1466-1475.
24. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499.
25. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, and Baillie TA (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62-70.
26. Klon AE, Lowrie JF, and Diller DJ (2006) Improved naïve Bayesian modeling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction. J Chem Inf Model 46:1945-1956.
27. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474-485.
28. Maciá MA, Carvajal A, del Pozo JG, Vera E, and del Pino A (2002) Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System. Clin Pharmacol Ther 72:596-597.
29. Marechal JD, Yu J, Brown S, Kapelioukh I, Rankin EM, Wolf CR, Roberts GC, Paine MJ, and Sutcliffe MJ (2006) In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab Dispos 34:534-538.
30. Metz JT, Huth JR, and Hajduk PJ (2007) Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups. J Comput Aided Mol Des 21:139-144.
31. O'Brien SE and de Groot MJ (2005) Greater than the sum of its parts: combining models for useful ADMET prediction. J Med Chem 48:1287-1291.
32. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, and Williams DP (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45:177-202.
33. Parker JC (2002) Troglitazone: the discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus. Adv Drug Deliv Rev 54:1173-1197.
34. Pearce BC, Sofia MJ, Good AC, Drexler DM, and Stock DA (2006) An empirical process for the design of high-throughput screening deck filters. J Chem Inf Model 46:1060-1068.
35. Prathipati P, Ma NL, and Keller TH (2008) Global Bayesian models for the prioritization of antitubercular agents. J Chem Inf Model 48:2362-2370.
36. Rogers D, Brown RD, and Hahn M (2005) Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 10:682-686.
37. Schuster D, Laggner C, and Langer T (2005) Why drugs fail - a study on side effects in new chemical entities. Curr Pharm Des 11:3545-3559.
38. Ung CY, Li H, Yap CW, and Chen YZ (2007) In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol 71:158-168.
39. Walgren JL, Mitchell MD, and Thompson DC (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 35:325-361.
40. Walters WP and Murcko MA (2002) Prediction of 'drug-likeness.' Adv Drug Del Rev 54:255-271.
41. Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, and Kasten LE (2007) Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf 30:805-815.
42. Willett P (2003) Similarity-based approaches to virtual screening. Biochem Soc Trans 31:603-606.
43. Williams AJ, Tkachenko V, Lipinski C, Tropsha A and Ekins S (2009) Free online resources enabling crowdsourced drug discovery. Drug Discovery World Winter 10:33-39.
44. Xia X, Maliski EG, Gallant P, and Rogers D (2004) Classification of kinase inhibitors using a Bayesian model. J Med Chem 47:4463-4470. (Pubitemid 39096834)
45. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, and de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:97-105.
46. Zheng X, Ekins S, Raufman JP, and Polli JE (2009) Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm 6:1591-1603.
47. Zientek M, Stoner C, Ayscue R, Klug-McLeod J, Jiang Y, West M, Collins C, and Ekins S (2010) Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol 23:664-676.